-
Product Insights
NewNet Present Value Model: PainReform Ltd’s Ropivacaine ER
Empower your strategies with our Net Present Value Model: PainReform Ltd's Ropivacaine ER report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: AstraZeneca Plc’s Datopotamab deruxtecan
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Datopotamab deruxtecan report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Orforglipron Calcium in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orforglipron Calcium in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orforglipron Calcium in Obesity Drug Details: Orforglipron calcium (LY-3502970) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ropivacaine ER in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropivacaine ER in Post-Operative Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ropivacaine ER in Post-Operative PainDrug Details:Ropivacaine ER (PRF-110) is under development for...
-
Product Insights
Net Present Value Model: Ropivacaine ER
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Ropivacaine ER Drug Details Ropivacaine ER...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ropivacaine ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ropivacaine ER Drug Details Ropivacaine ER (PRF-110) is under development for the treatment of...
-
Product Insights
Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Post-Operative Pain pipeline market research report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for PostOperative Pain and features dormant...